HTG MOLECULAR DIAGNOSTICS, INC. Item 8.01 Other Events.
Update on Drug Discovery Partnering Initiative
While the Company is still early in its partnering discussions, the Company is pleased with the level of preliminary interest in its drug discovery platform from certain pharmaceutical companies that historically in-license candidates for preclinical development as part of their business model. The Company believes this interest is driven by HTG's highly differentiated approach to drug discovery - namely, the use of its proprietary transcriptomic profiling technologies, integrated with a machine learning-based chemical library design platform, to better-inform the design and selection of drug candidate molecules. This approach is expected to yield drug candidates with lower risk profiles and increased opportunities for development success, all while being faster and more cost-efficient than traditional approaches.
HTG looks forward to engaging with pharmaceutical companies globally to identify the best partners to carry forward the development of the Company's early portfolio of candidate molecules in oncology and neurodegenerative disease indications, as well as with pharmaceutical companies interested in using HTG's drug discovery engine with their own targets and libraries. Using its advanced transcriptomic profiling platform in conjunction with an AI-driven drug discovery engine, the Company has designed two generations of molecules that have demonstrated in vitro efficacy in model systems, both as a standalone therapy and in combination with the current standard of care. The most advanced discovery molecules are progressing through lead optimization studies and the Company expects that these efforts will support entry into preclinical development in the next several months.
Achievement of First Quarter Drug Discovery Business Milestones
As previously announced, HTG achieved three significant drug discovery business milestones in the first quarter of 2023.
HTG filed a patent application on
The second key milestone achieved during the first quarter was the use of the Company's proprietary HTG EdgeSeq RNA profiling platform to biologically interrogate the lead molecules. This data, along with other primary and secondary data, was then introduced into the Company's AI-driven drug discovery engine, resulting in the creation of a second generation of molecules. The second generation of molecules has been subjected to the same in vitro experiments as the first, demonstrating improved efficacy over the first generation of molecules. These results also demonstrate the utility of the AI-driven drug discovery engine in combination with high-quality full transcriptome data.
The third milestone achieved was the use of the Company's AI-driven drug discovery engine to design compounds using transcriptomic data as the starting point. These system-designed compounds showed highly similar characteristics to HTG's lead compounds that were designed starting with the target. These results demonstrate the ability of HTG's engine to design novel compounds based on transcriptomic data alone, which the Company believes will open other applications of this platform, including drug repurposing.
In addition to further advancing the Company's drug discovery platform, these first quarter efforts have significantly advanced candidate molecules through lead optimization for HTG's first oncology indication in liquid tumors, with a program in solid tumors expected to follow closely behind. This second target for the treatment of solid tumors has been selected and added to HTG's oncology portfolio, which also includes an early pipeline in neurodegenerative diseases.
--------------------------------------------------------------------------------
The Company made significant progress in the advancement of candidate molecules for its first target during the first quarter of 2023, using profiling study results to inform the selection and design of drug candidates, while further building its existing pipeline with additional oncology indications and neurodegenerative. The Company also further advanced its drug discovery engine, enabling HTG to not only select molecules but to design them. The Company constructed its engine in a manner that allows future scalability and flexibility for integrating multiple data streams, which the Company believes gives it the ability to continue to evolve its discovery platform going forward. Forward-Looking Statements
Statements contained in this report regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding the
expected benefits of HTG's drug discovery platform, including the ability of the
platform to better-inform the design and selection of drug candidate molecules
with lower risk profiles and increased opportunities for development success,
all while being faster and more cost-efficient than traditional approaches;
HTG's expectation of progressing through lead optimization studies and entering
into preclinical development for HTG's most advanced discovery molecules in the
next several months; HTG's plan to identify partners to carry forward the
development of the Company's early portfolio of candidate molecules in oncology
and neurodegenerative disease indications, as well as with pharmaceutical
companies interested in using HTG's drug discovery engine with their own targets
and libraries; the potential of HTG's AI-driven drug discovery engine; the
ability of HTG's engine to design novel compounds based on transcriptomic data
and its belief that doing so will open other applications of the platform
(including drug repurposing); HTG's expected pipeline advancement; expected
future scalability and flexibility in HTG's platform; and the capabilities of
HTG's technology. Words such as "designed to," "believe," "anticipate,"
"expect," "potential," "will" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
necessarily contain these identifying words. These forward-looking statements
are based upon management's current expectations, are subject to known and
unknown risks, and involve assumptions that may never materialize or may prove
to be incorrect. Actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a result of various
risks and uncertainties, including risks associated with the Company's ability
to enter into licensing, partnering or other transactions for programs or
candidates arising from the Company's drug discovery platform, which
transactions may not occur when anticipated, or at all; the risk that the
Company's drug discovery approach may not result in the selection or development
of a drug candidate; various risks associated with drug discovery and
development; the risk that the Company's technologies may not provide the
benefits that the Company expects; risks associated with the Company's ability
to develop and commercialize the Company's products; the risk that the Company's
products and services may not be adopted by biopharmaceutical companies or other
customers as anticipated, or at all; and risks related to the Company's need for
additional capital. These and other factors are described in greater detail in
the Company's filings with the
--------------------------------------------------------------------------------
© Edgar Online, source
